

September 13, 2024

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS
---	---

Dear Sir / Madam,

Sub: Press Release - Laurus Labs concludes successful USFDA Audit for API Manufacturing Facility at Hyderabad

We enclose a copy of the Press Release that is being issued by the Company in connection with USFDA audit for our API manufacturing facility at Hyderabad (DS-1, IKP Knowledge Park, Genome Valley, Shameerpet, Telangana) without any 483 observation.

Please take the above information on record.

Yours faithfully,

For **Laurus Labs Limited**

G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

Investors Relations

Vivek Kumar
+91 40 3980 4366
investorrelations@lauruslabs.com

Media Relations

Karthik C
+91 40 3980 4380 | 9030088669
mediarelations@lauruslabs.com

Press Release

FOR IMMEDIATE RELEASE

13 SEPTEMBER, 2024

Laurus Labs Concludes Successful US FDA Audit for API Manufacturing Facility at Hyderabad

Hyderabad, September 13, 2024: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company in India is pleased to announce the successful completion of the US Food and Drug Administration (US FDA) audit of its API manufacturing facility at Hyderabad. The audit concluded with zero Form 483 observations, reaffirming Laurus Labs commitment to maintaining the highest standards of quality, safety, and compliance.

The US FDA inspection, conducted from 9th to 13th September, focused on evaluating the facility's adherence to global regulatory requirements and best practices. Laurus Labs' API manufacturing facility, located at DS-1, IKP Knowledge Park, Genome Valley, Shameerpet, Telangana is instrumental in developing Active Pharmaceutical Ingredients, bolstering the company's ability to deliver high-quality, innovative pharmaceutical solutions to its global customers.

END

Corporate Office

2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India
T +91 40 6659 4333, 3980 4333, 2342 0500/501 F +91 40 6659 4320 / 3980 4320

Registered Office

Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India
CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com

About Laurus Labs

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions of people around the world. Laurus has a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. Laurus also offers integrated Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus is passionate about continuous technological advances for Smart and Green chemistry technologies to drive efficiencies and sustainable manufacturing backed by proven regulatory and quality foundation. Laurus employs 6500+ people, including around 1250+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated "BBB" by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.